摘要
目的:细胞增殖抗原标记物(Ki-67)为细胞增殖的一个重要生物学指标,本研究旨在探讨Ki-67在良、恶性胸腹水的液基细胞涂片中的表达差异及其临床意义。方法:本实验收集恶性胸腹水标本49例作为恶性组,良性胸腹水标本25例作为良性组。用液基薄层细胞学检查(thin-layer cytology test,TCT)法对所有标本进行制片后,采用免疫组织化学染色法检测恶性组和良性组的涂片中Ki-67蛋白的表达,在光学显微镜下观察并利用图像分析系统进行半定量分析。结果:恶性组Ki-67表达的阳性率明显高于良性胸腹水组(P<0.01);恶性组Ki-67阳性细胞平均标记指数(M L1)高于良性组(P<0.05);恶性组Ki-67蛋白表达的相对含量明显高于良性组,两组相比有显著性差异(P<0.01)。恶性组与良性组Ki-67表达分析显示两组间在性别、年龄、病史方面无显著性差异(P>0.05)。结论:Ki-67可作为恶性胸腹水诊断的一个新的生物标记物,对鉴别良、恶性胸腹水有一定的参考价值。利用TCT方法,有利于提高细胞制片质量,便于胸腹水性质的判断、
Objective: This study aims to investigate the expression and significance of Ki-67 in their cell smears ofpleural effusion and ascites, using the thin-layer cytology test. Methods: This study involved 49 and 25 cases of malignant and benign pleural and peritoneal effusions, respectively. Immunohistochemical staining method was used to detect Ki-67 expression in the cell smears of both malignant and benign groups after all samples underwent cell smearing via thin-layer cytology test under an optical microscope. Semi-quantitative analysis was performed using an image analysis system. Results: The antigen expression of Ki-67 positive cells of the malignant group was significantly higher than that of the benign group ( P 〈 0.01 ). Moreover, the MLI of Ki-67 in the malignant group was higher than that in the benign group ( P 〈 0.05 ). The relative protein content of the Ki-67 positive cells in the malignant group was also significantly higher than that in the benign group ( P 〈 0.01 ). However, the Ki-67 expression in both groups were not significantly different in terms of gender, age, and illness history ( P 〉 0.05 ). Conclusion: The Ki-67 expression in pleural effusion and ascites can be used as a new biomarker in the early diagnosis of malignant pleuroperitoneal effusions. The results of this study can help identify the clinical nature of pleural effusion and ascites. Thin-layer cytology test is also a convenient and effective method for identifying malignant pleural effusion and ascites.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2012年第6期318-321,共4页
Chinese Journal of Clinical Oncology